A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects

This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase the systemic exposure of BMS-626529.

Inclusion Criteria:

• Healthy male and female
• Nonsmoking subjects
• Ages 18 to 50 years
• Inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive
• Women of childbearing potential
• Must agree to follow instructions for methods of contraception for the duration of the study plus 34 days post-treatment completion

Exclusion Criteria:

• Any history of acute or chronic medical and surgical illness.
• Personal of family history of hemophilia A or B
• Other protocol defined exclusion criteria could apply